PT2385   Click here for help

GtoPdb Ligand ID: 12707

Synonyms: MK-3795 | MK3795 | PT-2385
PDB Ligand
Compound class: Synthetic organic
Comment: PT2385 is a small-molecule antagonist of HIF2α that was designed for antitumour activity [1,3-5]. The molecule binds to an allosteric site on HIF2α and blocks its interaction with its dimerisation partner ARNT (aryl hydrocarbon receptor nuclear translocator, a.k.a. HIF1β). This action inhibits expression of HIF2α-dependent genes (e.g., VEGFA, PAI-1, and cyclin D1) in renal cancer models (cell lines and xenografts).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 95.77
Molecular weight 383.34
XLogP 0.9
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CS(=O)(=O)C1=CC=C(C2=C1[C@@H](C(C2)(F)F)O)OC3=CC(=CC(=C3)C#N)F
Isomeric SMILES FC1=CC(OC2=C3C([C@H](O)C(F)(F)C3)=C(S(=O)(C)=O)C=C2)=CC(C#N)=C1
InChI InChI=1S/C17H12F3NO4S/c1-26(23,24)14-3-2-13(12-7-17(19,20)16(22)15(12)14)25-11-5-9(8-21)4-10(18)6-11/h2-6,16,22H,7H2,1H3/t16-/m0/s1
InChI Key ONBSHRSJOPSEGS-INIZCTEOSA-N
References
1. Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P et al.. (2016)
Targeting renal cell carcinoma with a HIF-2 antagonist.
Nature, 539 (7627): 112-117. [PMID:27595394]
2. Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM et al.. (2018)
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
J Clin Oncol, 36 (9): 867-874. [PMID:29257710]
3. Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E. (2017)
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Crit Rev Oncol Hematol, 111: 117-123. [PMID:28259286]
4. Toledo RA. (2017)
New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Endocr Relat Cancer, 24 (9): C9-C19. [PMID:28667082]
5. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS et al.. (2016)
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
Cancer Res, 76 (18): 5491-500. [PMID:27635045]